Item 2.01 Completion of Acquisition or Disposition of Assets.
The disclosures under the Introductory Note and Item 3.01 are incorporated herein by reference.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
The disclosures under the Introductory Note are incorporated herein by reference.
On
--------------------------------------------------------------------------------
Item 3.03 Material Modification to Rights of Security Holders.
The disclosures under the Introductory Note, Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference.
Item 5.01 Changes in Control of Registrant.
The disclosures under the Introductory Note, Item 3.01, Item 5.02 and Item 5.03 are incorporated herein by reference.
As a result of the consummation of the Offer and the Merger, there was a change in control of Pandion, and Merck, as the direct parent of Merger Sub, acquired control of Pandion. To the knowledge of Pandion, there are no arrangements which may at a subsequent date result in a further change in control of Pandion.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Pursuant to the Merger Agreement, as of the Effective Time,
Pursuant to the Merger Agreement, as of the Effective Time, the directors and
officers of Merger Sub immediately prior to the Effective Time became the
directors and officers of the
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change of Fiscal Year.
Pursuant to the terms of the Merger Agreement, as of the Effective Time, Pandion's certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the "Second Restated Certificate of Incorporation"). In addition, pursuant to the terms of the Merger Agreement, at the Effective Time, Pandion's by-laws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety (the "Amended and Restated By-Laws").
Copies of the Second Restated Certificate of Incorporation and the Amended and Restated By-Laws are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Number Description 2.1 Agreement and Plan of Merger, datedFebruary 24, 2021 , amongPandion Therapeutics, Inc. ,Merck Sharp & Dohme Corp. and Panama Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Pandion's Current Report on Form 8-K filed with theSEC onFebruary 25, 2021 ).* 3.1 Second Restated Certificate of Incorporation ofPandion Therapeutics, Inc. , datedApril 1, 2021 . 3.2 Amended and Restated By-Laws ofPandion Therapeutics, Inc. , datedApril 1, 2021 . * Schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules to theU.S. Securities and Exchange Commission upon request.
--------------------------------------------------------------------------------
© Edgar Online, source